Why the study?
Does a diet and exercise weight loss intervention improve blood pressure variability and vascular markers in patients with metabolic syndrome?
Does a diet and exercise weight loss intervention improve blood pressure variability and vascular markers in patients with metabolic syndrome?
Answers are grounded in this paper and cite their sources.
Weight reduction through diet and exercise improves blood pressure variability and vascular markers in patients with metabolic syndrome and high baseline blood pressure variability, independent of absolute blood pressure reduction.
It has long been clear that hypertension contributes to cardiovascular and kidney disease. In describing the relationship between elevations in systolic or diastolic blood pressure (BP) and individual outcomes such as stroke, ischemic heart disease, peripheral vascular disease, or even kidney disease over the past couple of decades, there has been an increasing interest in various subgroups that may drive this risk. Many investigators have sought to explore whether other cardiovascular risk factors such as dyslipidemia, diabetes, and obesity drive this risk while others have sought more ethnic, cultural, or other socioeconomic variables. However, there has been increasing interest in the presence of distinct phenotypes in BP patterns that drive this risk.1 Unfortunately, most of the larger clinical trial data did not include out-of-office home readings that represent more ambient-level BP responses to neurohumoral or hormonal variation as well as situational stressors. In this context, BP variability (BPV) in the short- and long-term has emerged as an important risk modifier of cardiovascular and kidney outcomes.1, 2 BPV represents a wide range of disorders from nocturnal dipping status and morning BP surge to orthostatic BP regulation. Measurement of BPV is best performed by 24-hour ambulatory BP monitoring, which can capture shorter-term variability such as beat-to-beat, minute-to-minute, hour-to-hour, and day-to-night measurements, or home monitoring, which may capture longer-term variability such as seasonal or yearly. Much of the work to date would support that BPV, especially dipping status and minute-to-minute or hourly monitoring, improves prognostication for cardiovascular and kidney outcomes.1 However, there is very little information to date on risk interventions that may improve BPV. In this regard, the investigation from Marcus and colleagues3 in the Journal is unique. The authors utilized a smaller cohort of patients (N=44) in an Israeli population with the metabolic syndrome as classified by the Third Report of the Adult Treatment Panel (ATP III) criteria, with the exception of prediabetes, wherein individuals with fasting glucose >100 mg/dL but without type 2 diabetes were included. The team then performed baseline 24-hour ambulatory BP monitoring and categorized the cohort into either low or high BPV (eg, lower or higher than the daytime standard deviation of 11.6 mm Hg observed in this population).4 This analytic approach is somewhat unique and warrants further validation in other populations. The entire cohort underwent an aggressive dietary and exercise intervention to target a 5% weight loss at 6 months and 10% at 12 months. Participants were given a basic Mediterranean diet in noncontrolled environments (eg, home) coupled with personalized physical training that was coached at a minimum of 3 times per week and a maximum of 5 times per week. The team tracked compliance and adherence to the prescribed protocol. In addition to tracking BPV at the beginning and end of the trial, the team captured data on intima-media thickness via carotid ultrasound, arterial stiffness via pulse wave velocity, and various biomarkers such as asymmetric dimethylarginine (ADMA). Essentially the authors reported that patients with the metabolic syndrome who displayed high BPV had more significant improvements at study end in each of the indices measured, including pulse wave velocity, carotid intima-media thickness, and various biomarkers such as glycated hemoglobin, ADMA, and C-reactive protein. It is notable there were no differences at baseline between those with high vs those with low BPV. At 1-year follow-up, both groups displayed reductions in metabolic parameters of weight (eg, body mass index, regional measures of adiposity, and lipids) but interestingly not BP. The finding that weight reduction did not lead to improvements in BP is somewhat surprising, yet may be the result of the smaller nature of the cohort, the relatively mild BP level (treated and prehypertensive patients; systolic BP ~126–127 mm Hg in both arms), the overweight phenotype of the cohort (eg, body mass index ~30 kg/m2 in both arms), or possibly the lack of sodium restriction in the dietary intervention. What is of real interest and value from the study is the finding that weight reduction in the metabolic population that displayed high BPV led to improvements in variability as well as the various markers measured. While the observation of improvements in metabolic parameters such as glycated hemoglobin, lipids, and ADMA, as well as imaging of stiffness and intima-media thickness is not surprising with the weight loss intervention in this cohort, the associative findings in those with high BPV is unique and worthy of notice. To date, BPV has had important prognostic significance for cardiovascular and kidney disease.1, 2 There has been little information gleaned from human studies on interventions that can improve BPV. Studies from preclinical models suggest that antihypertensive interventions improve variability5; however, there is significant confounding caused by BP reduction alone that may improve nitric oxide bioavailability, baroreflex sensitivity, and other mechanisms that may contribute to increases in variability. What little is known from human studies is similarly confounded by BP reduction.2, 6, 7 The report from Marcus and colleagues provides some unique findings including weight reduction without significant changes in BP can improve variability. The only other somewhat comparable report suggested that weight loss improved variability but was confounded by BP reductions and loss of the effect following the weight loss intervention.8 In that report, 34 men and women with the metabolic syndrome completing a 1-year weight loss intervention (mean ~14.6 kg) also had reductions in ambulatory BPs and low-frequency heart rate variability. These effects were largely lost during following 1 year of weight maintenance. The net effect of these two studies suggest that weight loss/interventions in a metabolic population improve heart rate and/or BPV. The current study sets the stage for further, future investigation into strategies that may target BPV. The report from Marcus and colleagues has provided an understanding of which population would benefit most from a targeted weight loss intervention, improving long-term outcomes on cardiovascular and kidney disease.
No takes yet. Share an insight, caveat, or question.
Whaley‐Connell et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: